Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 273-298

  Chen, Yu ^a   Palczewski, Krzysztof ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blindness; Network; Pharmacological agents; Polypharmacology; Retina; Systems biology

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; AGENTS ACTING ON THE EYE; DORZOLAMIDE PLUS TIMOLOL; DOXAZOSIN; G PROTEIN COUPLED RECEPTOR; GUANABENZ; GUANFACINE; KETANSERIN; LOFEXIDINE; N (2 HYDROXYCYCLOPENTYL) 1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXAMIDE; NEFAZODONE; PRAZOSIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOID; RITANSERIN; RS 23579 190; SGS 518; TAMSULOSIN; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ANOPHTHALMIA; ARTICLE; CELL STRESS; DIABETIC RETINOPATHY; EYE FUNDUS ALBIPUNCTATUS; FUNCTIONAL GENOMICS; GENE MUTATION; HUMAN; LEBER CONGENITAL AMAUROSIS; MICROPHTHALMIA; NONHUMAN; POLYPHARMACOLOGY; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA INJURY; RETINITIS; RETINITIS PIGMENTOSA; RETINOPATHY; SECOND MESSENGER; TRANSCRIPTOMICS; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

ANIMALS; DIABETIC RETINOPATHY; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; RETINAL DEGENERATION; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSCRIPTOME;

EID: 84954187087     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103033     Document Type: Article

References (101)

1. Zhao S, Iyengar R. 2012. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu. Rev. Pharmacol. Toxicol. 52:505-21
2. Xie L, Xie L, Kinnings SL, Bourne PE. 2012. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu. Rev. Pharmacol. Toxicol. 52:361-79
3. Boran AD, Iyengar R. 2010. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel. 13:297-309
4. Franci G, Miceli M, Altucci L. 2010. Targeting epigenetic networks with polypharmacology: A new avenue to tackle cancer. Epigenomics 2:731-42
5. Morrow JK, Tian L, Zhang S. 2010. Molecular networks in drug discovery. Crit. Rev. Biomed. Eng. 38:143-56
6. Hopkins AL. 2008. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol. 4:682-90
7. Gujral TS, Peshkin L, Kirschner MW. 2014. Exploiting polypharmacology for drug target deconvolution. PNAS 111:5048-53
8. Xie XQ, Wang L, Liu H, Ouyang Q, Fang C, SuW. 2014. Chemogenomics knowledgebased polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands. Front. Pharmacol. 5:3
9. Reddy AS, Zhang S. 2013. Polypharmacology: drug discovery for the future. Expert Rev. Clin. Pharmacol. 6:41-47
10. Brown JB, Okuno Y. 2012. Systems biology and systems chemistry: new directions for drug discovery. Chem. Biol. 19:23-28
11. Zhao S, NishimuraT,Chen Y, Azeloglu EU, GottesmanO, et al. 2013. Systems pharmacology of adverse event mitigation by drug combinations. Sci. Transl. Med. 5:206ra140
12. Colinge J, Rix U, Bennett KL, Superti-Furga G. 2012. Systems biology analysis of protein-drug interactions. Proteomics Clin. Appl. 6:102-16
13. Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, et al. 2012. Predicting new indications for approved drugs using a proteochemometric method. J. Med. Chem. 55:6832-48
14. Orth AP, Batalov S, Perrone M, Chanda SK. 2004. The promise of genomics to identify novel therapeutic targets. Expert Opin. Ther. Targets 8:587-96
15. Chua HN, Roth FP. 2011. Discovering the targets of drugs via computational systems biology. J. Biol. Chem. 286:23653-58
16. Iskar M, Zeller G, Zhao XM, van Noort V, Bork P. 2012. Drug discovery in the age of systems biology: The rise of computational approaches for data integration. Curr. Opin. Biotechnol. 23:609-16
17. Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, et al. 2012. Automated design of ligands to polypharmacological profiles. Nature 492:215-20
18. Hansen J, Zhao S, Iyengar R. 2011. Systems pharmacology of complex diseases. Ann. N. Y. Acad. Sci. 1245:E1-5
19. Berger SI, Iyengar R. 2009. Network analyses in systems pharmacology. Bioinformatics 25:2466-72
20. Wist AD, Berger SI, Iyengar R. 2009. Systems pharmacology and genomemedicine: A future perspective. Genome Med. 1:11
21. Margineanu DG. 2014. Systems biology, complexity, and the impact on antiepileptic drug discovery. Epilepsy Behav. 38:131-42
22. Margineanu DG. 2012. Systems biology impact on antiepileptic drug discovery. Epilepsy Res. 98:104-15
23. Roth BL, Sheffler DJ, Kroeze WK. 2004. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3:353-59
24. Piatigorsky J, Wistow GJ. 1989. Enzyme/crystallins: gene sharing as an evolutionary strategy. Cell 57:197-99
25. Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, et al. 2014. B-crystallin: A novel regulator of breast cancer metastasis to the brain. Clin. Cancer Res. 20:56-67
26. Slingsby C, Wistow GJ. 2014. Functions of crystallins in and out of lens: roles in elongated and postmitotic cells. Prog. Biophys. Mol. Biol. 115:52-67
27. Schomburg D, Michal G. 2012. Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology. Hoboken, NJ: Wiley
28. Lehar J, Krueger AS, Zimmermann GR, Borisy AA. 2009. Therapeutic selectivity and the multi-node drug target. Discov. Med. 8:185-90
29. Mason JS, Bortolato A, Congreve M, Marshall FH. 2012. New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol. Sci. 33:249-60
30. George AJ, Hannan RD, Thomas WG. 2013. Unravelling the molecular complexity ofGPCR-mediated EGFR transactivation using functional genomics approaches. FEBS J. 280:5258-68
31. LiuW, Chun E, Thompson AA, Chubukov P, Xu F, et al. 2012. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232-36
32. Katritch V, Cherezov V, Stevens RC. 2013. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53:531-56
33. Brugarolas M, Navarro G, Martnez-Pinilla E, Angelats E, Casadó V, et al. 2014. G-protein-coupled receptor heteromers as key players in the molecular architecture of the central nervous system. CNS Neurosci. Ther. 20:703-9
34. Dudley JT, Schadt E, Sirota M, Butte AJ, Ashley E. 2010. Drug discovery in a multidimensional world: systems, patterns, and networks. J. Cardiovasc. Transl. Res. 3:438-47
35. Iyengar R. 2013. Complex diseases require complex therapies. EMBO Rep. 14:1039-42
36. Mustafi D, Kevany BM, Genoud C, Okano K, Cideciyan AV, et al. 2011. Defective photoreceptor phagocytosis in a mouse model of enhanced S-cone syndrome causes progressive retinal degeneration. FASEB J. 25:3157-76
37. Mustafi D, Maeda T, Kohno H, Nadeau JH, Palczewski K. 2012. Inflammatory priming predisposes mice to age-related retinal degeneration. J. Clin. Investig. 122:2989-3001
38. AstraZeneca. 2004. Gefitinib (IRESSATM) lung cancer ISEL trial shows no overall survival advantage in a highly refractory population. News Release, Dec 17. http://www. Astrazeneca. com/Media/Pressreleases/Article/20041217-GEFITINIB-IRESSA-LUNG-CANCER-ISEL-TRIAL-SHOWSNO-O
39. Rask-Andersen M, Masuram S, Schiöth HB. 2014. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54:9-26
40. Russ AP, Lampel S. 2005. The druggable genome: An update. Drug Discov. Today 10:1607-10
41. Hopkins AL, Groom CR. 2002. The druggable genome. Nat. Rev. Drug Discov. 1:727-30
42. HigashiMK, Veenstra DL, Kondo LM,Wittkowsky AK, Srinouanprachanh SL, et al. 2002. Association between CYP2C9 genetic variants and anticoagulation-related outcomes duringwarfarin therapy. JAMA 287:1690-98
43. Lindh JD, Holm L, Andersson ML, Rane A. 2009. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65:365-75
44. Taylor JS, Ellis GR. 2002. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure. Am. J. Cardiovasc. Drugs 2:389-99
45. ExnerDV, DriesDL, Domanski MJ,Cohn JN. 2001. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N. Engl. J. Med. 344:1351-57
46. Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, et al. 2013. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLOS ONE 8:e57639
47. Bilello JA. 2005. The agony and ecstasy of "OMIC" technologies in drug development. Curr. Mol. Med. 5:39-52
48. Loeb JA. 2011. Identifying targets for preventing epilepsy using systems biology. Neurosci. Lett. 497:205-12
49. Butcher EC. 2005. Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov. 4:461-67
50. Butcher EC, Berg EL, Kunkel EJ. 2004. Systems biology in drug discovery. Nat. Biotechnol. 22:1253-59
51. Li JJ, Corey EJ. 2013. Drug Discovery: Practices, Processes, and Perspectives. Hoboken, NJ: Wiley
52. Chanda SK, Caldwell JS. 2003. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today 8:168-74
53. Fischer HP. 2005. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol. Annu. Rev. 11:1-68
54. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. 2009. Predicting new molecular targets for known drugs. Nature 462:175-81
55. Feil R, FragaMF. 2011. Epigenetics and the environment: emerging patterns and implications. Nat. Rev. Genet. 13:97-109
56. Bodnar AG, Ouellette M, FrolkisM,Holt SE, Chiu CP, et al. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-52
57. MullinsRF, Russell SR,AndersonDH, HagemanGS. 2000. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14:835-46
58. Hopkins AL. 2009. Drug discovery: predicting promiscuity. Nature 462:167-68
59. Barbaric I, MillerG,Dear TN. 2007. Appearances can be deceiving: phenotypes of knockout mice. Brief. Funct. Genomics Proteomics 6:91-103
60. Lombard DB, Beard C, Johnson B, Marciniak RA, Dausman J, et al. 2000. Mutations in the WRN gene in mice accelerate mortality in a p53-null background. Mol. Cell. Biol. 20:3286-91
61. Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, et al. 2013. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. PNAS 110:E517-25
62. Hoppe G, Lee TJ, Yoon S, Yu M, Peachey NS, et al. 2014. Inducing a visceral organ to protect a peripheral capillary bed: Stabilizing hepatic HIF-1prevents oxygen-induced retinopathy. Am. J. Pathol. 184:1890-99
63. Higgins CF. 2007. Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749-57
64. Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. 2012. Merging systems biology with pharmacodynamics. Sci. Transl. Med. 4:126ps7
65. Lagerström MC, SchiöthHB. 2008. Structural diversity ofGprotein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7:339-57
66. Chen Y, Palczewska G, Mustafi D, Golczak M, Dong Z, et al. 2013. Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. J. Clin. Investig. 123:5119-34
67. Chen Y, Okano K,Maeda T, Chauhan V,Golczak M, et al. 2012. Mechanism of all-trans-retinal toxicity with implications for Stargardt disease and age-related macular degeneration. J. Biol. Chem. 287:5059-69
68. Pierce KL, Premont RT, Lefkowitz RJ. 2002. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3:639-50
69. Gilman AG. 1984. G proteins and dual control of adenylate cyclase. Cell 36:577-79
70. Gilman AG. 1987. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56:615-49
71. Oldham WM, Hamm HE. 2008. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 9:60-71
72. Ritter SL, Hall RA. 2009. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 10:819-30
73. Mujíc-Delíc A, deWit RH, Verkaar F, Smit MJ. 2014. GPCR-targeting nanobodies: Attractive research tools, diagnostics, and therapeutics. Trends Pharmacol. Sci. 35:247-55
74. Fredriksson R, Höglund PJ, Gloriam DEI, Lagerström MC, Schiöth HB. 2003. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett. 554:381-88
75. Lambert AJ, Brand MD. 2004. Superoxide production by NADH:ubiquinone oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner membrane. Biochem. J. 382:511-17
76. Puntarulo S, Cederbaum AI. 1998. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic. Biol. Med. 24:1324-30
77. Geiszt M. 2006. NADPH oxidases: new kids on the block. Cardiovasc. Res. 71:289-99
78. Bedard K, Krause KH. 2007. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87:245-313
79. Lambeth JD, Kawahara T, Diebold B. 2007. Regulation of Nox and Duox enzymatic activity and expression. Free Radic. Biol. Med. 43:319-31
80. Griendling KK, SorescuD, Ushio-Fukai M. 2000. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86:494-501
81. Li JM, Shah AM. 2003. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J. Am. Soc. Nephrol. 14:S221-26
82. Holmstrom KM, Finkel T. 2014. Cellular mechanisms and physiological consequences of redoxdependent signalling. Nat. Rev. Mol. Cell Biol. 15:411-21
83. Nauseef WM. 2008. Nox enzymes in immune cells. Semin. Immunopathol. 30:195-208
84. Barki-Harrington L, Luttrell LM, RockmanHA. 2003. Dual inhibition of-adrenergic and angiotensin II receptors by a single antagonist: A functional role for receptor-receptor interaction in vivo. Circulation 108:1611-18
85. Pepe S, van den Brink OWV, Lakatta EG, Xiao RP. 2004. Cross-talk of opioid peptide receptor and adrenergic receptor signalling in the heart. Cardiovasc. Res. 63:414-22
86. SmithNJ, Luttrell LM. 2006. Signal switching, crosstalk, and arrestin scaffolds: novelGprotein-coupled receptor signaling in cardiovascular disease. Hypertension 48:173-79
87. Maeda A, Palczewski K. 2014. Retinal degeneration in animal models with a defective visual cycle. Drug Discov. Today Dis. Models 10:e163-72
88. Maeda A, Maeda T, Golczak M, Chou S, Desai A, et al. 2009. Involvement of all-trans-retinal in acute light-induced retinopathy of mice. J. Biol. Chem. 284:15173-83
89. Du Y, Veenstra A, Palczewski K, Kern TS. 2013. Photoreceptor cells are major contributors to diabetesinduced oxidative stress and local inflammation in the retina. PNAS 110:16586-91
90. Brechard S, Tschirhart EJ. 2008. Regulation of superoxide production in neutrophils: role of calcium influx. J. Leukoc. Biol. 84:1223-37
91. Du Y, Cramer M, Lee CA, Tang J, Muthusamy A, et al. 2015. Adrenergic and serotonin receptors affect retinal superoxide generation in diabetic mice: relationship to capillary degeneration and permeability. FASEB J. 29:2194-204
92. Wilkinson-Berka JL, Deliyanti D, Rana I, Miller AG, Agrotis A, et al. 2014. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid. Redox Signal. 20:2726-40
93. Pujol A, Mosca R, Farres J, Aloy P. 2010. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol. Sci. 31:115-23
94. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. 2010. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol. Cancer Ther. 9:3137-44
95. Sever PS,Messerli FH. 2011. Hypertension management 2011: optimal combination therapy. Eur. Heart J. 32:2499-506
96. Khouri AS, Realini T, Fechtner RD. 2007. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 24:1007-16
97. Hantschel O, Superti-Furga G. 2012. Cell biology: A key driver of therapeutic innovation. J. Cell Biol. 199:571-75
98. Civelek M, Lusis AJ. 2014. Systems genetics approaches to understand complex traits. Nat. Rev. Genet. 15:34-48
99. Katritch V, Cherezov V, Stevens RC. 2012. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 33:17-27
100. Maeda A, Palczewska G, Golczak M, Kohno H, Dong Z, et al. 2014. Two-photon microscopy reveals early rod photoreceptor cell damage in light-exposed mutant mice. PNAS 111:E1428-37
101. Palczewski K, Orban T. 2013. From atomic structures to neuronal functions of G protein-coupled receptors. Annu. Rev. Neurosci. 36:139-64